Drug development

#Cancer research #Drug development #Genetics / genomes #Laboratory data #Research

‘Patchwork’ tumours prevalent across multiple cancer types

Researchers at the Francis Crick Institute, as part of an international collaboration of scientists through the Pan-Cancer Analysis of Whole Genomes Consortium, have analysed the whole genomes of tumour samples from over 2,600 patients with different types of cancer. They identified a high prevalence of genetic diversity within individual tumours,… Read More

#Cancer Research #News

#Alzheimer's #Biotechnology #Biotherapeutics #Clinical trials #Drug development #Therapeutics

Clinical Ink adds 16th concurrent Alzheimer’s study

Clinical Ink, a clinical trial technology company, has announced the addition of its 16th concurrent Phase II/III Alzheimer’s disease study, exemplifying its ongoing commitment to this therapeutic area. Clinical Ink’s platform supports the needs of sponsors working on Alzheimer’s trials by using direct collection tools that allow for flexible data… Read More

#News

#Drug delivery #Drug development #Rare disease

Sanofi makes access to essential medicines commitment

Sanofi CEO Paul Hudson has outlined key projects that the company will implement to increase the impact of its Corporate Social Responsibility (CSR) strategy. The company’s commitment is based on: access to medicines, support for vulnerable communities, preservation of the environment, and inclusion and diversity of its employees. “The pandemic… Read More

#News

#Drug development #Drug discovery #Generics #Pharmaceuticals

Drug discovery and India: the future looks bright

As the world’s largest generic producer how far advanced is India’s drug discovery push and where does it stand on the global stage? Lu Rahman explores. India has become a key player in the global pharmaceutical sector. The value of its part in this industry is expected to reach $120… Read More

#Covid-19 #Editor's Choice #Exclusive Content #Intelligence #Market Reports #News

#Biotherapeutics #Drug development #Drug discovery #Novel therapeutics

Infex’s resistance bypass drug program ready for clinic

Infex Therapeutics has appointed Pharmaron to help progress its MET-X program which targets urinary tract infections caused by World Health Organisation (WHO) critical-priority resistant Gram-negative bacteria. Pharmaron will manufacture the patented molecule at its plant in Hoddesdon, Hertfordshire. On completion of this stage of the work, MET-X will go through… Read More

#News

#Clinical trials #Covid-19 #Drug development #Immunology / Virology & Vaccines #Vaccines

Valneva reports positive Phase I/II data for Covid-19 vaccine

Valneva, a specialty vaccine company focused on the development and commercialisation of prophylactic vaccines for infectious diseases with significant unmet medical need, has announced positive data for Part A of the Phase I/II clinical trial of its inactivated, adjuvanted Covid-19 vaccine candidate, VLA2001. Based on this data, the company plans… Read More

#Covid-19 #News

#Clinical trial #Covid-19 #Drug development #Drug discovery #Immunology / Virology & Vaccines

Novavax initiates Covid-19 vaccine clinical trial crossover

Biotech company Novavax has announced the initiation of crossover arms in two ongoing clinical trials of NVX-CoV2373, the company’s Covid-19 vaccine candidate. Crossover ensures the administration of active vaccine to all participants in the trials and has begun for Novavax’ Phase IIb trial in South Africa and its pivotal Phase… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Database #Drug development #Drug discovery #Laboratory data #Life sciences

Genemod launches platform to improve lab automation

Genemod is now offering free and paid plans for life science labs worldwide for its cloud-based platform. This is focused on inventory management and lab notebook solutions, enabling collaboration and data sharing between teammates. Genemod helps reduce back and forth time spent through traditional data entry methods, as well as… Read More

#News

#Assay #Bioscience #Biotechnology #Drug development #Kinetics #Research #Screening #Video

NanoBRET technology enables the study of the interaction of compounds

Aurelia Bioscience is a pre-clinical contract research organisation specialising in bioassay development, pharmacological profiling and compound screening. Scientists at Aurelia Bioscience have experience developing new and innovative bio-assays for different target classes using technologies to deliver client projects in a timely, efficient and cost-effective manner. Using Promega’s NanoBRET… Read More

#News #Videos

#Covid-19 #Drug development #Drug discovery #Immunology / Virology & Vaccines #Life sciences #Narrated podcasts

Vaccine innovation in the age of Covid-19

This is the latest episode of the free DDW podcast, titled Vaccine innovation in the age of Covid-19. It covers two narrated articles written for DDW and read aloud by Megan Thomas. These articles are titled: “Vaccine innovation in the age of Covid-19 & beyond” and “Creating vaccines: Why we… Read More

#Podcasts

#Automation / robotics #Drug development #Drug discovery

Automation that connects your drug discovery workflow

Scientific and technological advancements continue to emphasise the importance of automation, both in the physical and digital world. Given recent discussions about the lab of the future, the benefits have expanded to highlight how automation can support greater connectivity between data and workflows, paving the way to a ‘smarter lab’. Read More

#News

#Biotherapeutics #Drug development #Immunology / Virology & Vaccines #Vaccines

ENPICOM accelerates antibody and vaccine discovery

Viroclinics-DDL, a Contract Research Organisation (CRO) specialising in molecular diagnostic testing and assay development, and ENPICOM, a bioinformatics software engineering company, have announced the approval of a joint MIT Zuid subsidy (SME Innovation Stimulation Top Sectors South Holland) application. This R&D partnership project combines in vitro diagnostic and high-throughput sequencing… Read More

#News

#Covid-19 #Drug delivery #Drug development #Immunology / Virology & Vaccines #Vaccines

GSK to support manufacture of Novavax’ Covid-19 vaccine

Novavax, a biotechnology company developing next-generation vaccines for serious infectious diseases, GSK and the UK Government Vaccines Taskforce announced that they have reached an agreement in principle to support manufacturing of up to 60 million doses of Novavax’ Covid-19 vaccine candidate (NVX-CoV2373) for use in the UK. GSK will provide… Read More

#Covid-19 #News

#Covid-19 #Drug development #Immunology / Virology & Vaccines #Research

Modelling and simulation facilitates drug repurposing to counter Covid-19

By Dr Craig R. Rayner, FRCP Edin, PharmD, MBA, President, Integrated Drug Development at Certara Right at the start of the Covid-19 pandemic, medical researchers began questioning whether there were any existing, on-market drugs that might prove effective against SARS-CoV-2. They wanted to offer healthcare professionals and patients some known… Read More

#Business & Investment #Exclusive Content #News

#Dementia #Drug development #Drug discovery #Muscles #Research

Scientists study how signals from muscles can protect from dementia

Scientists at St. Jude Children’s Research Hospital are studying how signals sent from skeletal muscle affect the brain. The team studied fruit flies and brain cell models called organoids, focusing on the signals that muscles send when stressed. They used immunostaining and confocal microscopy on the fruit fly brain and… Read More

#News

#Awards #Cell therapy #Drug development #Therapeutics

Mogrify wins awards for innovation and named business of the year

Mogrify, a UK company which aims to transform the development of ex vivo cell therapies and pioneer the field of in vivo reprogramming therapies, has been awarded the Hewitsons Award for Innovation in Business and Price Bailey Award for Business of the Year at the CambridgeshireLive Business Excellence Awards 2020. Read More

#News